Placeholder Banner

BIO Applauds Senate Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Legislation will strengthen pipeline of medical countermeasures against serious public health threats

May 17, 2019
Media Contact
BIO logo

Washington, DC (May 17, 2019) – The Biotechnology Innovation Organization (BIO) today applauds the Senate passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act (S. 1379). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS). The legislation also authorizes funding for pandemic influenza product development and procurement for the first time.

The following statement may be attributed to BIO President and CEO Jim Greenwood:

“Over the past 16 years, federal biodefense programs have spurred the creation of dozens of medical countermeasures by the biotechnology industry, greatly improving our nation’s preparedness to respond to the many known and unknown chemical, biological, radiological and nuclear threats (CBRN) facing our nation,” said BIO President and CEO Jim Greenwood. “But as the number and scale of threats continues to grow, these programs are needed now more than ever."

“This bipartisan legislation will provide critical flexibility and predictability for government agencies and their private sector partners by authorizing increased, multi-year funding for the BioShield Special Reserve Fund and by empowering BARDA to better address CBRN threat agents, pandemic influenza, emerging infectious diseases, and antimicrobial resistance. The investments in preparedness and medical countermeasure development enabled by this legislation will save lives, enhance our response efforts, and be more cost effective in an emergency.”

“I thank Senators Richard Burr, Bob Casey, as well as HELP Committee Chairman Lamar Alexander and Ranking Member Patty Murray for their bipartisan leadership crafting and advancing this critical legislation. In addition, I applaud Senator Tammy Baldwin for her championship of pandemic influenza preparedness, which will significantly bolster our nation’s ability to respond to the emergence of novel influenza viruses.”

Discover More
BIO-Led Summit to Build Collaboration Between Biopharma Industry, Government Leaders & Scientific Experts  Responding to the rapidly evolving COVID-19 public health crisis, the Biotechnology Innovation Organization (BIO) is taking the…
Washington, DC – February 21, 2020 - The Biotechnology Innovation Organization (BIO) announced today, it is canceling the annual BIO Asia conference in Tokyo scheduled for March 10-11. The decision was based on the global impact of COVID-19 and…
President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination…